Chester County News and Community Website
WILMINGTON, DE — AstraZeneca has launched a national cancer awareness campaign aimed at increasing biomarker testing among U.S. patients, addressing a gap in cancer care as the pharmaceutical industry increasingly …
AstraZeneca Targets Cancer Testing Gap With New Campaign Read More WILMINGTON, DE — AstraZeneca’s experimental cancer drug sonesitatug vedotin reduced the risk of death by 53% in patients receiving third-line or later treatment for advanced gastric and related cancers, according …
AstraZeneca Drug Cuts Death Risk in Advanced Gastric Cancer Read More WILMINGTON, DE — AstraZeneca’s TAGRISSO combined with savolitinib extended median survival by nearly five months compared with chemotherapy in a Phase III trial involving patients with EGFR-mutated non-small cell lung …
AstraZeneca Drug Combination Extends Lung Cancer Survival Read More WILMINGTON, DE — AstraZeneca’s IMFINZI combined with Amgen’s tarlatamab-dlle extended median survival to 21.1 months in patients with extensive-stage small cell lung cancer, compared with 12.7 months for IMFINZI alone, …
AstraZeneca Drug Combination Extends Lung Cancer Survival Read More WILMINGTON, DE — AstraZeneca has launched ZEGFROVY (sunvozertinib) in the United States for adults with a specific form of advanced lung cancer that has progressed following platinum-based chemotherapy, expanding access …
AstraZeneca Launches Targeted Lung Cancer Drug in U.S. Read More
WILMINGTON, DE — AstraZeneca and Amgen reported that their immunotherapy TEZSPIRE significantly reduced esophageal inflammation and swallowing difficulties in a Phase III clinical trial, strengthening the companies’ case for expanding …
AstraZeneca, Amgen Report Phase III Success for TEZSPIRE Read More WILMINGTON, DE — AstraZeneca has opened a new research and development center in Cambridge, Massachusetts, as part of a more than $1 billion investment expected to expand its workforce in …
AstraZeneca Opens $1 Billion R&D Hub, Plans 50% Workforce Growth Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) application to expand Imfinzi into another form of bladder cancer has received FDA Priority Review after a Phase III trial showed the drug combination …
FDA Speeds Review of AstraZeneca Bladder Cancer Regimen Read More WILMINGTON, DE — AstraZeneca (NYSE: AZN) and Daiichi Sankyo’s Enhertu extended median progression-free survival by six months versus pembrolizumab plus chemotherapy in a Phase III trial of first-line treatment for …
Enhertu Extends PFS by Six Months in HER2 Lung Cancer Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) Tagrisso showed a sustained survival benefit eight years after treatment in a Phase III trial of patients with early-stage EGFR-mutated non-small cell lung cancer, …
Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial Read More